Teva Total Other Income Expense Net vs Reconciled Depreciation Analysis
TEVA Stock | USD 16.14 0.16 0.98% |
Teva Pharma financial indicator trend analysis is much more than just breaking down Teva Pharma Industries prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Teva Pharma Industries is a good investment. Please check the relationship between Teva Pharma Total Other Income Expense Net and its Reconciled Depreciation accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
Total Other Income Expense Net vs Reconciled Depreciation
Total Other Income Expense Net vs Reconciled Depreciation Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Teva Pharma Industries Total Other Income Expense Net account and Reconciled Depreciation. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Teva Pharma's Total Other Income Expense Net and Reconciled Depreciation is -0.08. Overlapping area represents the amount of variation of Total Other Income Expense Net that can explain the historical movement of Reconciled Depreciation in the same time period over historical financial statements of Teva Pharma Industries, assuming nothing else is changed. The correlation between historical values of Teva Pharma's Total Other Income Expense Net and Reconciled Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Other Income Expense Net of Teva Pharma Industries are associated (or correlated) with its Reconciled Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Reconciled Depreciation has no effect on the direction of Total Other Income Expense Net i.e., Teva Pharma's Total Other Income Expense Net and Reconciled Depreciation go up and down completely randomly.
Correlation Coefficient | -0.08 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Total Other Income Expense Net
Reconciled Depreciation
Most indicators from Teva Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Teva Pharma Industries current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. At present, Teva Pharma's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 40.5 B, whereas Tax Provision is forecasted to decline to (7.3 M).
2021 | 2023 | 2024 (projected) | Interest Expense | 1.1B | 1.0B | 1.1B | Depreciation And Amortization | 1.3B | 1.2B | 667.3M |
Teva Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Teva Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Teva Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 57.5B | 50.6B | 47.7B | 44.0B | 43.5B | 26.4B | |
Short Long Term Debt Total | 27.3B | 26.4B | 23.5B | 21.6B | 20.2B | 21.2B | |
Other Current Liab | 890M | 931M | 903M | 6.0B | 1.1B | 1.6B | |
Total Current Liabilities | 13.7B | 13.2B | 11.0B | 11.5B | 12.2B | 6.5B | |
Total Stockholder Equity | 14.0B | 10.0B | 10.3B | 7.9B | 7.5B | 9.9B | |
Property Plant And Equipment Net | 7.0B | 6.9B | 6.5B | 6.2B | 6.1B | 3.2B | |
Net Debt | 25.4B | 24.2B | 21.3B | 18.8B | 16.9B | 17.8B | |
Retained Earnings | (7.0B) | (10.9B) | (10.5B) | (12.9B) | (13.5B) | (12.9B) | |
Cash | 2.0B | 2.2B | 2.2B | 2.8B | 3.2B | 3.4B | |
Non Current Assets Total | 44.0B | 37.6B | 35.1B | 32.0B | 31.0B | 18.7B | |
Non Currrent Assets Other | 591M | 538M | 515M | 441M | 462M | 594.6M | |
Cash And Short Term Investments | 2.0B | 2.2B | 2.2B | 2.8B | 3.2B | 3.4B | |
Net Receivables | 5.7B | 4.6B | 4.5B | 3.7B | 3.4B | 3.0B | |
Common Stock Shares Outstanding | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B | 777.0M | |
Liabilities And Stockholders Equity | 57.5B | 50.6B | 47.7B | 44.0B | 43.5B | 26.4B | |
Non Current Liabilities Total | 28.7B | 26.4B | 25.4B | 23.8B | 23.1B | 24.3B | |
Inventory | 4.4B | 4.4B | 3.8B | 3.8B | 4.0B | 2.4B | |
Other Current Assets | 434M | 710M | 967M | 549M | 505M | 914.4M | |
Other Stockholder Equity | 23.2B | 23.3B | 23.4B | 23.6B | 23.7B | 24.9B | |
Total Liab | 42.4B | 39.6B | 36.4B | 35.3B | 35.4B | 37.1B | |
Total Current Assets | 13.5B | 13.0B | 12.6B | 12.1B | 12.5B | 7.7B | |
Short Term Debt | 2.3B | 3.2B | 1.4B | 2.1B | 1.7B | 1.3B | |
Intangible Assets | 11.2B | 8.9B | 7.5B | 6.3B | 5.4B | 4.7B | |
Accounts Payable | 1.7B | 1.8B | 1.7B | 1.9B | 2.6B | 2.1B | |
Accumulated Other Comprehensive Income | (2.3B) | (2.4B) | (2.7B) | (2.8B) | (2.7B) | (2.6B) | |
Other Liab | 3.7B | 3.2B | 3.4B | 4.4B | 5.1B | 5.3B | |
Other Assets | 2.1B | 1.1B | 1M | (1M) | 1.9B | 950K | |
Long Term Debt | 24.6B | 22.7B | 21.6B | 19.1B | 18.2B | 12.5B | |
Property Plant Equipment | 6.4B | 6.3B | 6.0B | 6.2B | 7.1B | 4.8B | |
Current Deferred Revenue | 8.7B | 7.3B | 7.0B | 1.5B | 6.9B | 7.3B | |
Good Will | 24.8B | 20.6B | 20.0B | 17.6B | 17.2B | 17.7B | |
Property Plant And Equipment Gross | 6.4B | 6.9B | 6.5B | 6.2B | 11.8B | 12.4B | |
Short Long Term Debt | 2.3B | 3.2B | 1.4B | 2.1B | 1.7B | 2.6B | |
Net Tangible Assets | (22.1B) | (19.5B) | (17.2B) | (16.0B) | (14.4B) | (15.1B) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Teva Stock analysis
When running Teva Pharma's price analysis, check to measure Teva Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharma is operating at the current time. Most of Teva Pharma's value examination focuses on studying past and present price action to predict the probability of Teva Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharma's price. Additionally, you may evaluate how the addition of Teva Pharma to your portfolios can decrease your overall portfolio volatility.
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
CEOs Directory Screen CEOs from public companies around the world | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Teva Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (0.42) | Revenue Per Share 14.277 | Quarterly Revenue Growth 0.043 | Return On Assets 0.0484 |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.